1435479-63-2

Basic information

• Product Name: 4-fluoro-5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid
• Synonyms: 4-fluoro-5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid
• CAS NO: 1435479-63-2
• Molecular Weight: 0
• Mol File: 1435479-63-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-fluoro-5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-fluoro-5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid(1435479-63-2)
• EPA Substance Registry System: 4-fluoro-5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid(1435479-63-2)

Safety Data

• Hazardous Substances Data: 1435479-63-2(Hazardous Substances Data)

Upstream product

• 82846-18-2 4?fluoro-3-methoxybenzoic acid 
• 288-36-8 1,2,3-triazole 
• 1007455-21-1 2-bromo-4-fluoro-5-methoxy-benzoic acid 

Downstream Products

• 1597520-01-8 (4-fluoro-5-methoxy-2-[1,2,3]triazol-2-ylphenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]pyrrolidin-1-yl}methanone 

Relevant articles and documents

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep-Promoting Properties in Rats

The orexin system plays an important role in the regulation of wakefulness. Suvorexant, a dual orexin receptor antagonist (DORA) is approved for the treatment of primary insomnia. Herein, we outline our optimization efforts toward a novel DORA. We started our investigation with rac-[3-(5-chloro-benzooxazol-2-ylamino)piperidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-ylphenyl)methanone (3), a structural hybrid of suvorexant and a piperidine-containing DORA. During the optimization, we resolved liabilities such as chemical instability, CYP3A4 inhibition, and low brain penetration potential. Furthermore, structural modification of the piperidine scaffold was essential to improve potency at the orexin 2 receptor. This work led to the identification of (5-methoxy-4-methyl-2-[1,2,3]triazol-2-ylphenyl)-{(S)-2-[5-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-3-yl]pyrrolidin-1-yl}methanone (51), a potent, brain-penetrating DORA with in vivo efficacy similar to that of suvorexant in rats.

AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to